《大行報告》中金下調閱文(00772.HK)目標價至47元 料上半年非國際會計準測淨利潤按年跌12.9%
中金發表評級報告,預料閱文(00772.HK)上半年收入按年跌14.2%至35.1億元人民幣,非國際會計準測淨利潤按年跌12.9%至5.8億元人民幣。
該行指,集團線上業務表現持續穩健,而公司今年仍將關注於提升經營效率,考慮到2022年基數效應以及公司效率提升策略,預計今年上半年銷售及行政支出(SG&A)費用按年跌6.7%至15.6億元人民幣。
中金表示,將公司今年非國際會計準測淨利潤預測下調11%至16億元人民幣,明年則下調14.5%至19億元人民幣,目標價相應下調9.6%至47元,維持「跑贏行業」評級。(ca/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.